Shilpa Pharma Lifesciences Ltd, Unit II, Raichur, Karnataka has cleared PMDA Japan, GMP inspection

Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited's Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has undergone a GMP inspection by PMDA, Japan starting 29th August 2023. The inspection has concluded successfully on 1st September 2023 without any critical/major observation.

The facility is involved in manufacturing various oncology and non‐oncology APIs.

The company remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 370.95 as compared to the previous close of Rs. 369.70. The total number of shares traded during the day was 8790 in over 389 trades.

The stock hit an intraday high of Rs. 376.05 and intraday low of 368.90. The net turnover during the day was Rs. 3276598.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 ShilpaPharmaLifesciences APIFacility Raichur GMPInspection PMDA Japan